Bionic nano-particles with antithrombotic function as well as preparation method and application of bionic nano-particles

A biomimetic nanometer and nanoparticle technology, applied in the field of biomimetic nanoparticle and its preparation, can solve the problems of increasing the biological half-life of macrophages, impairing the hemostatic ability, and affecting the effect of thrombolysis, so as to improve bioavailability, prolong circulation half-life, The effect of improving serum stability

Active Publication Date: 2022-07-29
HUAZHONG AGRI UNIV
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the current thrombus-targeted drug delivery system still has shortcomings, which can be summarized as follows: 1) The degradation safety of polymer materials used in the drug delivery system needs to be further evaluated. How to avoid immunogenicity and prolong drug delivery Systemic blood circulation time and how to choose safe and degradable polymer materials are still the difficulties in the research and development of efficient and safe thrombus-targeted drug delivery system
2) The modified short peptide targeting molecule is exogenous, which can easily trigger the body’s immune response, increase the phagocytosis of the drug delivery system by macrophages and reduce its biological half-life, thereby affecting the thrombolytic effect
3) Excessive use of traditional thrombolytic drugs and antithrombotic drugs will impair normal hemostasis and lead to bleeding complications

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Bionic nano-particles with antithrombotic function as well as preparation method and application of bionic nano-particles
  • Bionic nano-particles with antithrombotic function as well as preparation method and application of bionic nano-particles
  • Bionic nano-particles with antithrombotic function as well as preparation method and application of bionic nano-particles

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0048] This embodiment is to prepare a biomimetic nanoparticle with antithrombotic function. The preparation process of the biomimetic nanoparticle and the technical route of thrombolysis are as follows: figure 1 shown. details as follows:

[0049] 1) Extraction of melanin nanoparticles (M NPs): such as figure 2 As shown, thaw 200-500g of frozen cuttlefish at room temperature for 1-2 hours, cut it from the back with a scalpel, remove the hard shell of the cuttlefish on the back, find the black ink sac and take it out, discard the outer skin to obtain black particles, It was dissolved in water, centrifuged at a speed of 2000r / min for 10min, discarded the precipitate, took the supernatant, and then centrifuged at a speed of 8000r / min for 20min, discarded the supernatant, took the precipitate, and obtained the melanin nanoparticles for use.

[0050] 2) Extraction of platelet membrane (Pm): Platelets were isolated from whole blood of ICR mice by differential centrifugation. Th...

Embodiment 2

[0054] In this example, the biomimetic nanoparticles (MAHP) with antithrombotic function prepared in Example 1 were characterized by their morphology and their dispersion properties were measured.

[0055] 1) Morphology characterization: The MNPs, MNPs@COF and MCHP prepared in Example 1 were prepared into 2 mg / mL solutions, respectively, and 2 μL were dropped on the copper grid for overnight sample preparation at room temperature, or at 70 °C for 3 The sample was dried for 1 hour; then photographed by transmission electron microscope, the results are as follows Figure 4 It can be seen from the figure that MNPs, MNPs-COF and MCHP are all nanoparticles with uniform particle size and regular shape, and the particle size of MCHP is 100-200 nm.

[0056] 2) Determination of dispersity: The particle size and Zeta potential of MCHP were determined by using a Malvern Zetasizer Nano ZS90 instrument. The measurement parameters are set as: laser 6 mW; incident wavelength 633 nm; scatter...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
angleaaaaaaaaaa
Login to view more

Abstract

The invention discloses bionic nano-particles with an antithrombotic function and a preparation method and application thereof, melanin nano-particles are extracted from ink sacs of cuttlefishes, platelet membranes are extracted from mouse blood, natural hirudin is wrapped in COF grafted outside the melanin nano-particles, then the platelet membranes are wrapped outside the natural hirudin for camouflage, and the bionic nano-particles with the antithrombotic function are obtained. Therefore, thrombus targeted thrombolysis treatment is realized. Natural hirudin is wrapped in COF outside melanin nanoparticles, the degradation effect of protease is reduced, the clearing speed of the natural hirudin in vivo is delayed, the bioavailability of the natural hirudin is improved, and in the long-term treatment process, the hirudin is slowly released and forms an irreversible compound with thrombin, so that recurrence of thrombus is inhibited. In addition, the platelet membrane is used for targeted positioning, body immune response does not exist, and the blood-pressure-sensitive hydrogel has good safety. And the bionic nanoparticles are combined with photothermal, so that the effect of rapid thrombolysis is achieved, and the biomimetic nanoparticles have good medical application prospects and practical value.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to a biomimetic nanoparticle with antithrombotic function and a preparation method and application thereof. Background technique [0002] A thrombus is a blood clot formed by damage to vascular endothelial cells, abnormalities of the coagulation system, and / or changes in blood rheology. The main components of a thrombus include activated platelets, red blood cells, and fibrin. Once a blood clot blocks a major blood vessel, ischemia and hypoxia can occur in downstream tissues, leading to tissue necrosis. For example, carotid artery embolism can lead to ischemia and hypoxia in brain tissue, resulting in tissue necrosis and neurological dysfunction. Therefore, after a thrombus occurs, it is necessary to perform surgery in time or use thrombolytic drugs to eliminate the thrombus, and in order to avoid the re-formation of thrombus, postoperative patients need to continue to take me...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K41/00A61K38/58A61K9/51A61K47/69A61K47/46A61P7/02
CPCA61K41/0052A61K38/58A61K9/5176A61K47/6949A61P7/02A61K2300/00
Inventor 韩鹤友李书挺
Owner HUAZHONG AGRI UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap